FDA
-
-
-
-
-
-
-
Pacira BioSciences to sell iovera° unit to Zimmer Biomet for up to $140M
-
-
-
-
-
-
-
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders
-
-
-
-
-
-
-
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back
-
-
-
-
-
-
-
Pacira BioSciences faces generic challenge to EXPAREL pain drug
-
-
-
-
-
-
-
Pacira BioSciences partners with J&J MedTech to expand ZILRETTA reach
-
-
-
-
-
-
-
Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis
-
-
-
-
-
-
-
Pacira Pharmaceuticals (PCRX) PT Raised to $21 at JPMorgan
-
329,303 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

